Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.67 Average Target Price from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been given an average rating of “Moderate Buy” by the nine brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $17.67.

A number of analysts have weighed in on the company. Barclays increased their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Piper Sandler increased their price target on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of Alphatec in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th.

Insider Buying and Selling at Alphatec

In other news, CEO Patrick Miles sold 12,691 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $10.64, for a total value of $135,032.24. Following the transaction, the chief executive officer now owns 5,857,603 shares in the company, valued at $62,324,895.92. The trade was a 0.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Sponsel sold 33,732 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total value of $365,317.56. Following the completion of the transaction, the executive vice president now owns 668,977 shares in the company, valued at $7,245,020.91. The trade was a 4.80 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 337,321 shares of company stock worth $3,828,060. Insiders own 22.80% of the company’s stock.

Hedge Funds Weigh In On Alphatec

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Lido Advisors LLC boosted its stake in shares of Alphatec by 8.4% in the 4th quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company’s stock worth $112,000 after buying an additional 953 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Alphatec by 0.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock valued at $2,873,000 after purchasing an additional 1,120 shares during the last quarter. Comerica Bank lifted its stake in Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in Alphatec by 14.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company’s stock valued at $100,000 after purchasing an additional 1,342 shares during the last quarter. Finally, Atria Investments Inc lifted its stake in Alphatec by 8.0% in the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after purchasing an additional 1,460 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Stock Up 0.2 %

Shares of NASDAQ:ATEC opened at $9.29 on Friday. The firm has a market cap of $1.34 billion, a P/E ratio of -7.26 and a beta of 1.39. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec has a 12-month low of $4.88 and a 12-month high of $14.88. The business has a fifty day simple moving average of $10.95 and a 200 day simple moving average of $8.76.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The company had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. Analysts predict that Alphatec will post -1.08 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.